About

Metavalis Inc. is a strategic bioengineering firm operating at the intersection of molecular physics and quantum artificial intelligence. We are executing a high velocity operation to commercialize a non viral functional therapeutic for Crigler-Najjar Syndrome Type 1 (CNS1).
​Unlike traditional biotech firms relying on immunogenic viral vectors (AAV), Metavalis utilizes Smart LNP 3.0 a proprietary, biodegradable delivery platform engineered with Polysarcosine Stealth technology to enable chronic re-dosing without toxicity.
​Our R&D is guided by the Metavalis Universal Constructor Protocol, a sovereign, quantum neuromorphic AI architecture designed to simulate biological interactions and optimize delivery vectors. We operate with a "Failure Doctrine" that views disease not as biological bad luck, but as an engineering failure to be corrected.
​Metavalis is currently ranked in the Top 1% of Global Startups on Crunchbase and is filing foundational IP in both advanced materials and autonomous AI Self Aware Conciousness.